PDGFRA mutation	Gastrointestinal Stromal Tumor	PDGFRA mutation	Gastrointestinal Stromal Tumor	imatinib Sensitive: A2 - Guideline imatinib Sensitive : A2	imatinib Sensitive: A2 - Guideline imatinib Sensitive : A2
PDGFRA mutation	Gastrointestinal Stromal Tumor	PDGFRA mutation	Gastrointestinal Stromal Tumor	ripretinib Sensitive: B - Late Trials ripretinib Sensitive : B	ripretinib Sensitive: B - Late Trials ripretinib Sensitive : B
PDGFRA mutation	Gastric Cancer	PDGFRA mutation	Gastric Cancer	imatinib Sensitive: B - Late Trials imatinib Sensitive : B	imatinib Sensitive: B - Late Trials imatinib Sensitive : B
PDGFRA mutation	Gastrointestinal Stromal Tumor	PDGFRA mutation	Gastrointestinal Stromal Tumor	avapritinib Sensitive: C2 – Inclusion Criteria avapritinib Sensitive : C2	avapritinib Sensitive: C2 – Inclusion Criteria avapritinib Sensitive : C2
PDGFRA mutation	Non Small Cell Lung Cancer	PDGFRA mutation	Non Small Cell Lung Cancer	nintedanib Sensitive: C3 – Early Trials nintedanib Sensitive : C3	nintedanib Sensitive: C3 – Early Trials nintedanib Sensitive : C3
PDGFRA mutation	Non Small Cell Lung Cancer	PDGFRA mutation	Non Small Cell Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
PDGFRA mutation	Gastrointestinal Stromal Tumor	PDGFRA mutation	Gastrointestinal Stromal Tumor	AZD1775 Sensitive: D – Preclinical AZD1775 Sensitive : D	AZD1775 Sensitive: D – Preclinical AZD1775 Sensitive : D
PDGFRA mutation	Gastrointestinal Stromal Tumor	PDGFRA mutation	Gastrointestinal Stromal Tumor	AZD1775 + avapritinib Sensitive: D – Preclinical AZD1775 + avapritinib Sensitive : D	AZD1775 + avapritinib Sensitive: D – Preclinical AZD1775 + avapritinib Sensitive : D

PDGFRA mutation

Associations